DNDIDrugs for Neglected Diseases Initiative
DNDIDo Not Disturb, Individual (computing)
References in periodicals archive ?
Sanofi is developing fexinidazole in collaboration with the Drugs for Neglected Diseases initiative (DNDi).
WHO partnered with the Drugs for Neglected Diseases initiative (DNDi) to spearhead the issue.
Atendiendo al pedido de los paises de la region, Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi, por sus siglas en ingles), Medicos Sin Fronteras (MSF) y la OPS desarrollaron una herramienta de estimacion de demanda de los medicamentos antichagasicos (17).
It will provide guidance to new R&D initiatives such as the WHO/ Drugs for Neglected Diseases initiative (DNDi) Global Antibiotic R&D Partnership, which is engaging in not-for-profit development of new antibiotics.
Between 2004 and 2007, a fixed-dose combined formulation containing artesunate (AS) and amodiaquine (AQ) in a single tablet (ASAQ Winthrop) was developed by Sanofi in partnership with the Drugs for Neglected Disease initiative (DNDi) [11].
[31] "Drugs for Neglected Diseases Initiative DNDi R&D Projects," http://wwwdndi.org/diseases-projects/portfolio/.
Sanofi-Aventis, in partnership with Drugs for Neglected Diseases initiative (DNDi), through the Artesunate-Amodiaquine (ASAQ) program, developed a new antimalarial combination drug treatment that is designed to be available to the highest possible number of patients at low cost.
The session on infectious diseases this session was mainly focused on the contribution of Drug for Neglected Diseases initiative (DNDi), Switzerland in the field of neglected tropical diseases.
Pharco and Presidio also agreed to perform a large clinical trial on all HCV genotypes, together with the Drugs for Neglected Diseases Initiative (DNDI), in 2016.
1, 2014) (including partners, for example, Vertex Pharmaceuticals Inc., Erasmus Medical Center Rotterdam, Drugs for Neglected Diseases Initiative (DNDI), AstraZeneca, the Medicines Evaluation Board, and the Netherlands Vaccine Institute).
PHTI is a partnership between the MPP, UNITAID, the Drugs for Neglected Diseases initiative (DNDi) and the Clinton Health Access Initiative (CHAI).
Drugs for Neglected Diseases (DNDi), a non-profit research and development organisation developing new treatments for neglected diseases and supported by Medecins Sans Frontieres, has calculated that, of the 1,556 new drugs approved between 1975 and 2004, only 21 (1.3 per cent) were specifically developed for tropical diseases and tuberculosis, even though these diseases account for 11.4 per cent of the global disease burden.